Current management of chronic wounds involves regular wound cleaning, antiseptic dressings and, when indicated, antimicrobials. Micropore particle technology (MPPT) is a novel concept for wound healing, aiming to bolster the action of the immune system by disrupting the wound biofilm and restoring the microbiome. Amicapsil is the first MPPT product licensed for clinical use. Patients with a spinal cord injury (SCI) are more likely to develop chronic wounds due to downregulation in their immune response increasing the risk of a minor wound, such as pressure sore, developing into large, non-healing wounds. At the Defence Medical Rehabilitation Centre (DMRC) Stanford Hall, patients with SCI often have chronic wounds causing pain, becoming infected and preventing full engagement with effective rehabilitation. We report on the first case of treatment with Amicapsil at the DMRC Stanford Hall and review MPPT as a potential new paradigm for the treatment of wound healing.
Keywords: biotechnology & bioinformatics; rehabilitation medicine; wound management.
© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.